WAY-652848 is a selective inhibitor of SRPK1 with an IC50 value of 0.58 μM.WAY-652848 effectively reduces choroidal neovascularization (CNV) in vivo, and can be used in the study of age-related macular degeneration.
WAY-652848 is a selective inhibitor of SRPK1 with an IC50 value of 0.58 μM.WAY-652848 effectively reduces choroidal neovascularization (CNV) in vivo, and can be used in the study of age-related macular degeneration.
WAY-652848 is a selective inhibitor of SRPK1 with an IC50 value of 0.58 μM.WAY-652848 effectively reduces choroidal neovascularization (CNV) in vivo, and can be used in the study of age-related macular degeneration.
WDR5-0103 is a small molecule that binds a peptide-binding pocket on WDR5 (Kd = 450 nM), inhibiting the catalytic activity of the MLL core complex in vitro (IC50 = 39 µM).
WDR5-0103 is a small molecule that binds a peptide-binding pocket on WDR5 (Kd = 450 nM), inhibiting the catalytic activity of the MLL core complex in vitro (IC50 = 39 µM).
Wedelolactone, a medicinal plant-derived natural compound, is an inhibitor of IKK that is critical for activation of NF-κB by mediating phosphorylation and degradation of IκBα. Wedelolactone is also an inhibitor of caspase-11.
Wedelolactone, a medicinal plant-derived natural compound, is an inhibitor of IKK that is critical for activation of NF-κB by mediating phosphorylation and degradation of IκBα. Wedelolactone is also an inhibitor of caspase-11.
Wedelolactone, a medicinal plant-derived natural compound, is an inhibitor of IKK that is critical for activation of NF-κB by mediating phosphorylation and degradation of IκBα. Wedelolactone is also an inhibitor of caspase-11.